FFFidelity Disruptive Medicine ETF
23.72USDR
+0.23+0.98%
Last update at 20:15 GMT
USD
No tradesPost-market
Key stats
About Fidelity Disruptive Medicine ETF
Home page
Inception date
Jun 12, 2023
Structure
Open-Ended Fund
Replication method
Physical
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Fidelity Management & Research Co. LLC
Distributor
Fidelity Distributors Co. LLC
FMED seeks long-term capital appreciation by utilizing proprietary disruptive strategies in identifying companies involved in disruptive technologies for its portfolio. Disruptive technologies are innovations that may reshape how businesses currently deliver their services and operate, potentially displacing industry leaders over time. The fund primarily invests in growth and value stocks of companies tied with disruptive innovation in health care globally. This includes robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based healthcare platforms, advanced diagnostics, and consumer wellness. The adviser uses fundamental analysis, as well as economic and market conditions for its portfolio construction. The adviser may buy, sell, and hold decisions at their discretion. FMED converted from a mutual fund to an actively managed ETF, with $44 million in assets.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.78%
Health Technology78.75%
Technology Services8.93%
Health Services5.10%
Finance1.27%
Bonds, Cash & Other0.22%
Mutual fund6.32%
Cash−6.10%
Stock breakdown by region
North America83.45%
Europe15.07%
Asia1.48%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Symbol
Assets
Symbol
Assets
F
Fidelity Revere Street Trust Central Cash Collateral Fund
6.16%
B
Boston Scientific CorporationBSX
5.53%
A
Alnylam Pharmaceuticals, IncALNY
3.91%
V
Veeva Systems Inc Class AVEEV
3.64%
L
Legend Biotech Corp. Sponsored ADRLEGN
3.37%
D
Danaher CorporationDHR
3.34%
A
argenx SE Sponsored ADRARGX
3.29%
P
Insulet CorporationPODD
3.25%
I
Intuitive Surgical, Inc.ISRG
3.17%
W
Waystar Holding Corp.WAY
3.12%
Top 10 weight38.77%
69 total holdings
Dividends
Jun '24
Dec '24
0.00
0.03
0.06
0.09
0.12
Dividend amount
Dividend payout history
Ex-date
Record date
Pay date
Amount
Frequency
Dec 20, 2024
Dec 20, 2024
Dec 24, 2024
0.112
Quarterly
Jun 21, 2024
Jun 21, 2024
Jun 25, 2024
0.001
Other
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
FMED invests in stocks. The fund's major sectors are Health Technology, with 83.55% stocks, and Technology Services, with 9.48% of the basket. The assets are mostly located in the North America region.
FMED last dividends amounted to 0.11 USD. The quarter before, the issuer paid 0.00 USD in dividends, which shows a 99.11% increase.
FMED assets under management is 53.13 M USD. It's risen 1.37% over the last month.
FMED fund flows account for 2.35 M USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Yes, FMED pays dividends to its holders with the dividend yield of 0.48%. The last dividend (Dec 24, 2024) amounted to 0.11 USD. The dividends are paid quarterly.
FMED shares are issued by FMR LLC under the brand Fidelity. The ETF was launched on Jun 12, 2023, and its management style is Active.
FMED expense ratio is 0.50% meaning you'd have to pay 0.50% of your investment to help manage the fund.
FMED follows the No Underlying Index. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
FMED invests in stocks.
FMED price has fallen by −0.15% over the last month, and its yearly performance shows a −4.28% decrease. See more dynamics on FMED price chart.
NAV returns, another gauge of an ETF dynamics, showed a 5.76% increase in three-month performance and has decreased by −4.36% in a year.
NAV returns, another gauge of an ETF dynamics, showed a 5.76% increase in three-month performance and has decreased by −4.36% in a year.
FMED trades at a premium (0.00%) meaning the ETF is trading at a higher price than the calculated NAV.